Incidence of CNS metastases as first site of relapse was 3 % ( eight of 251 patients ) for lapatinib-capecitabine and 5 % ( 12 of 250 patients ) for trastuzumab-capecitabine ( treatment differences , -1.6 % ; 95 % CI , -2 % to 5 % ; P = .360 ) .